

# Interim results

Half year ended 30 September 2016




Robert Purcell  
Brian Tenner

CEO  
CFO

15 November 2016



## Operating margins maintained in volatile market conditions



- Chain division performing ahead of expectations, Torque Transmission behind

- Tooth Chain acquisition trading ahead of expectations, integration proceeding smoothly

- Strong operating cash flows enabled continued investment

- Ongoing actions to improve efficiency and lower breakeven point

- Modest growth expected in H2

- Confident of meeting full year expectations






# Re-engineering our future: Financial Performance

Brian Tenner, CFO

## Results deliver stabilisation after particularly weak H2 in prior year


	2017 Interim £m	2016 Interim £m	Var £m
Revenue as reported	88.3	84.5	+3.8
Impact of FX	-	7.5	-
<b>Underlying revenue</b>	<b>88.3</b>	<b>92.0</b> ↓	<b>(3.7)</b>
Reported adjusted operating profit	7.0	7.9	(0.9)
Impact of FX	-	1.1	-
<b>Underlying adjusted operating profit</b>	<b>7.0</b>	<b>9.0</b> ↓	<b>(2.0)</b>
<i>Underlying Return on Sales %</i>	<i>7.9%</i>	<i>9.8%</i>	<i>(1.9%)</i>
<b>Adjusted EPS</b>	<b>2.3p</b>	<b>2.5p</b> ↓	<b>(0.2p)</b>

- Underlying orders 0.2% ahead of PY
- Underlying sales down 4.0%
- Book to bill (B2B) ratio recovered to 101%
- Investment in people and activities to support growth related activities as well as extra depreciation on new factory assets
- Operating margins held at 7.9% with Adjusted EBITDA comfortable at £10.1m



## Key division maintaining forward momentum in sales and operating result


	2017 Interim £m	2016 Interim £m	Var %
Underlying revenue	71.1	69.8	↑ +1.9
Underlying adjusted operating profit	8.4	8.1	↑ +3.7
<i>Underlying Return on Sales %</i>	<b>11.8%</b>	11.6%	↑





- Order intake 4.7% ahead of H1 16
  - Europe over 10% ahead even without Tooth Chain acquisition
  - Other regions saw small falls
- Distribution and OEM orders firm in Europe (sales flat) whereas both channels were weak in sales and orders in the Americas
- Sales 1.9% ahead of H1 16
  - Growth in Europe and Australasia
  - H1 weakness in the Americas
  - B2B ratio 99%
- Major capital projects committed in H1
- Investment in business improvements and growth focused overheads
- Footprint rationalisation in Europe
- Tooth Chain out-performing expectations
- Chain target for operating margins remains mid-teens in a GDP+ growth environment



## Recovering trend from weakness in the prior year




- Orders and sales starting to recover
- Trend also exists on an organic basis
- Good correlation between order intake and sales in the same half year period
- Reflects the relatively short duration of the Chain order book – 3 month visibility
- Order intake and B2B trends point to continued recovery in H2 17




## Operating profit flat on H2 PY despite continuing difficult end markets

	2017 Interim £m	2016 Interim £m	Var %
Underlying revenue	17.2	22.2	↓ (22.5%)
Underlying adjusted operating profit	1.2	3.9	↓ (69.2%)
<i>Underlying Return on Sales %</i>	<b>7.0%</b>	17.6%	↓



- Underlying orders in TT were down 13.5%
- Fall in underlying sales broadly equivalent to the H2 PY fall in orders
- Demand soft in marine, land based power and US commodity related industries
- Variable margins maintained on H1 PY
- Overheads held flat while investing in actions to improve the business and its prospects
- Major UK couplings consolidation proposal announced for employee consultation
- Significant upgrade in UK Couplings manufacturing capabilities
- Subject to the consultation process, the project will bring major benefits to service, lead times, capital allocation and costs
- Short term TT goals to stabilise revenue and return to mid-teens operating margins



## Order intake gives improving outlook for H2 though markets remain volatile








- Underlying order intake in H1 17 shows a modest improvement on H2 16
- Prior year saw a clear step down in orders in H2 due to slowness in marine, land based power and US commodity sectors
- Longer TT lead times mean order variations take longer to feed into sales growth
- Better order intake and B2B trend point to sales levelling off towards the end of H2 17





## Lower financing costs and tax charges enhance earnings

	2017 Interim £m	2016 Interim £m	Var £m
<b>Adjusted operating profit</b>	<b>7.0</b>	<b>7.9</b>	 <b>(0.9)</b>
Exceptional items	(1.4)	(0.8)	(0.6)
Pension admin costs	(0.3)	(0.3)	-
Amortisation of acquired intangible assets	(0.5)	-	(0.5)
<b>Reported operating profit</b>	<b>4.8</b>	<b>6.8</b>	 <b>(2.0)</b>
Pension scheme interest	(1.3)	(1.3)	-
External financing charges	(0.7)	(0.8)	 +0.1
Other interest charges	(0.1)	(0.1)	-
<b>Profit before tax</b>	<b>2.7</b>	<b>4.6</b>	 <b>(1.9)</b>
Taxation	(0.6)	(0.9)	+0.3
<b>Profit after tax</b>	<b>2.1</b>	<b>3.7</b>	 <b>(1.6)</b>

- The main exceptional items were:
  - Tooth Chain transitional costs £0.2m
  - European distribution centre £0.4m
  - TT UK restructuring costs £0.6m
  - Other restructuring charges £0.2m
- Pension scheme interest unchanged as the impact of higher discount rates netted against lower opening deficits
- The amortisation of acquired intangibles relates to various assets acquired as part of the Tooth Chain transaction
- Financing charges lower due to full year benefit of May 2015 re-financing
- The Group holds tax assets that deliver the STEP 2020 ETR of 20% or lower
- Tax assets continue to be accessible as profitability improves

## Strong EBITDA supports expanded capital programme and acquisition funding


	2017 Interim £m	2016 Interim £m	Var £m
<b>Adjusted EBITDA</b>	<b>10.1</b>	<b>10.7</b>	<b>↓ (0.6)</b>
Movement in working capital	(2.6)	(2.5)	(0.1)
Pensions cash costs	(3.1)	(2.3)	(0.8)
Restructuring spend	(1.8)	(1.5)	(0.3)
Taxes and other	(0.6)	(0.4)	(0.2)
<b>Net cash from operating activities</b>	<b>2.0</b>	<b>4.0</b>	<b>↓ (2.0)</b>
Investing activities	(3.6)	(5.2)	+1.6
Financing costs paid	(0.7)	(1.1)	+0.4
Other movements / FX	(0.4)	0.2	(0.6)
<b>Change in net debt</b>	<b>(2.7)</b>	<b>(2.1)</b>	<b>↑ (0.6)</b>
Opening net debt	(23.5)	(19.5)	
<b>Closing net debt</b>	<b>(26.2)</b>	<b>(21.6)</b>	<b>↑ (4.6)</b>

- Good EBITDA maintained despite £3.7m fall in underlying sales
- Working capital movements reflect investments in strategic stock holdings and some slowing in customer payment patterns
- Pension cash spend increase reflects one off contribution to support PY insured buy in and FX impact – H2 costs will therefore fall
- Restructuring spend relates to:
  - Bredbury onerous lease payments and pre-sublease capital works
  - Tooth Chain transition costs
  - European Distribution Centre relocation costs
  - Proposed UK Couplings project
- Lower capital spend reflects late machine delivery for a large project in the US (£2.0m)
- Financing costs in H1 PY included up front costs of re-financing the Group's main RCF

## Improving asset base offset by market driven increase in pension deficit



	2017 Interim £m	2016 Interim £m	Var £m
Goodwill	25.0	21.4	+3.6
Intangible assets	10.0	6.5	+3.5
Fixed assets	48.6	40.9	+7.7
Deferred tax	21.3	16.3	+5.0
Inventories	41.2	36.0	+5.2
Receivables	34.1	28.1	+6.0
Payables	(39.3)	(33.4)	(5.9)
<b>Net working capital</b>	<b>36.0</b>	<b>30.7</b>	<b>+5.3</b>
Net Borrowings	(26.2)	(21.6)	(4.6)
Provisions	(5.9)	(5.8)	(0.1)
Pension deficit	(112.4)	(76.0)	(36.4)
Other	(1.4)	(1.1)	(0.3)
<b>Net (liabilities) / assets</b>	<b>(5.0)</b>	<b>11.3</b>	<b>(16.3)</b>
<b>Leverage<sup>(1)</sup> ratio</b>	<b>1.3x</b>	<b>1.0x</b>	

- Balance sheet impacted by FX changes
- Intangible assets acquired with the Tooth Chain business in January 2016
- Working capital includes £0.7m relating to the Tooth Chain acquisition
- Pension deficit driven by bond yields post Brexit and FX on the Euro
- Leverage remains comfortable (max 2.5x)



(1) Leverage is calculated as Net debt / adjusted EBITDA

## Cash funding remains stable with real gains from mortality and transfers



- Balance sheet deficit driven by post Brexit corporate bond yields – falling 1.2% in the UK and 0.6% in Germany – which have already improved by 0.4% by 31 October
- Partly offset by strong asset performance (growth and protection assets)
- PY medically underwritten buy ins effectively hedged 25% of the movement in bond yields
- UK experience gains (£5.5m) reflect mortality and member movements in excess of IAS19 assumptions over the last three years
- Cash contributions remain stable – one off UK £0.5m in respect of prior year pensioner buy in. Adverse FX will be largely offset by Australian closure and other UK cost savings
- Ongoing Triennial Review is focused on asset investment strategy as additional cash contributions will only happen if already agreed profit related mechanism is triggered
- Plc reserves protected by Group structure





Re-engineering our future:  
Next Steps

Robert Purcell, CEO

## STEP 2020 benefits offsetting market volatility

### Restructuring activities


- ✓ Consolidated European Distribution Centre into German warehouse serving major manufacturing plant - complete
- ✓ Consultation process underway to consolidate UK Couplings facilities
- ✓ New ERP system live in two sites with Tooth Chain next in line in Q3

### Growth activities

- ✓ New sales staff hired in multiple locations in Chain and TT
- ✓ Chain offices opened in Spain, underway for Poland, and two further locations in planning

### Structural activities

- ✓ Tooth Chain integration proceeding well, delivering incremental growth through Renold sales channels
- ✓ Surplus French property sold for £1.0m
- ✓ Pension de-risking continues



## Significant achievements delivered on each of our STEP 2020 'staircases'



### Health & Safety

- Risk management focus emphasising reduction in fire hazards
- Increasing buy in from all employees and rising standards

### Corporate Efficiency

- Bredbury sub-lease signed to deliver £0.7m p.a. cash savings
- Lower interest costs from 2015 re-financing

### Growth Activity

- Thailand and Benelux offices show benefits of local presence
- Sales approach increasingly application or industry specific

### Manufacturing Efficiency


- Major capital commitments in Chain plants around the world
- Significant upgrade to UK Couplings capabilities now online

### Process Efficiency

- Engineering systems roll out progressing well
- New Information Systems capabilities such as BI & barcoding

### Commercial Positioning

- Focused product management starting to show benefits
- Marketing activity up 70% supporting direct sales to end users



## STEP 2020 acquisition strategy identifies three different types of attractive acquisitions




- Tooth Chain acquisition trading ahead of expectations with sales and cost synergies growing
- Management transitioning to proactive approach to acquisitions
- Pipeline of opportunities exists in European and North American chain markets in particular
- Financing facilities and low leverage allow self-funding of smaller bolt-on deals

***Scale, reputation and expertise make Renold a natural consolidator in the Chain sector***





## Business stabilised and ready to regain positive momentum





# Appendices

## Significant volatility in foreign exchange rates continued in current year



- Sales denominated in US\$ represent approximately 35% of the group total, and 15% in Euro's.
- The primary impact of the volatility was with respect to translation.
- Illustratively, reported sales for the prior year of £165.2m are retranslated as £178.6m using the September 16 WAER. Prior year reported operating profit of £14.2m retranslates as £16.1m.
- However, FX rates remain volatile so predicting year end impact on the current year is not possible.

## Disclaimer

These presentation materials (the "Presentation Materials") are being solely issued to and directed at (a) persons having professional experience in matters relating to investments and who are investment professionals as specified in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotions Order"), and (b) persons certified as sophisticated investors within the meaning of Article 50 of the Financial Promotions Order but (for the avoidance of doubt) not those who are self-certified within the meaning of Article 50A of the Financial Promotions Order.

This document is exempt from the general restriction on the communication of invitations or inducements to enter into investment activity and has therefore not been approved by an authorised person as would otherwise be required by section 21 of the Financial Services and Markets Act 2000. Any investment to which this document relates is available to (and any investment activity to which it relates will be engaged with) only those persons described in (a) or (b) above. Persons who do not fall within the above categories of investor should not take any action upon this document, but should return it immediately to Arden Partners Plc, Corporate Finance department, 125 Old Broad Street, London, EC2N 1AR.

It is a condition of your receiving this document that (i) you fall within, and you warrant to Renold plc (the "Company") and Arden Partners Plc ("Arden Partners") that you fall within, one of the categories of person described in (a) or (b) above and (ii) if you fall within category (b) above, it is a condition of your receiving this document that (A) you are a person who has a current sophisticated investor certificate, signed by an authorised person and dated no earlier than 36 months preceding the date of receipt of this document, confirming that, in the opinion of such person, you are sufficiently knowledgeable to understand the risks associated with an investment in a Main Market quoted company and (B) that within the last 12 months you have signed a statement in the terms set out in Article 50(1)(b) of the Financial Promotions Order.

The Presentation Materials do not constitute an invitation or an inducement to engage in investment activity. Similarly, the Presentation Materials do not constitute or form any part of any offer or invitation to sell or issue or purchase or subscribe for any shares in the Company nor shall they or any part of them, or the fact of their distribution, form the basis of, or be relied on in connection with, any contract with the Company relating to any securities. The Presentation Materials are not intended to be distributed or passed on, directly or indirectly, or to any other class of persons. They are being supplied to you solely for your information and may not be reproduced, forwarded to any other person or published, in whole or in part, for any other purpose.

No reliance may be placed for any purpose whatsoever on the information contained in this document or on its completeness. Any reliance on this communication could potentially expose you to a significant risk of losing all of the property invested by you or the incurring by you of additional liability. No representation or warranty, express or implied, is given by the Company, its directors or employees, or Arden Partners or their professional advisers as to the accuracy, fairness, sufficiency or completeness of the information, opinions or beliefs contained in this document. Save in the case of fraud, no liability is accepted for any loss, cost or damage suffered or incurred as a result of the reliance on such information, opinions or beliefs. Recipients of these Presentation Materials should conduct their own investigation, evaluation and analysis of the business, data and property described in this document.

If you are in any doubt about the investment to which these Presentation Materials relate, you should consult a person authorised by the Financial Conduct Authority who specialises in advising on securities of the kind described in this document. Arden Partners will not be responsible in respect of such matters to any other person for providing protections afforded to customers of Arden Partners or for providing advice in relation to those matters.

The information presented here is not an offer for sale within the United States of any shares or any other security of the Company. Any shares referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration under that Act or an available exemption from it. The distribution of this document may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking" statements, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment, information technology and political, economic, legal and social conditions affecting the Company. These forward looking statements speak only as of the date of the Presentation Materials and accordingly you should not place undue reliance on such statements.